Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 1, 2014, Pages

  Roblin, Xavier ^a   Marotte, Hubert ^a   Rinaudo, Melanie ^a   Del Tedesco, Emilie ^a   Moreau, Amelie ^a   Phelip, Jean Marc ^a   Genin, Christian ^a   Peyrin Biroulet, Laurent ^b   Paul, Stephane ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Anti Adalimumab; Outcome; Prognostic Factor; Response to Therapy

Indexed keywords

ADALIMUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG MONITORING; ENTERITIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; HEALING; HUMAN; MAINTENANCE THERAPY; MALE; MULTIVARIATE ANALYSIS; PHARMACOKINETICS; REMISSION; SENSITIVITY AND SPECIFICITY; STOMACH MUCOSA INJURY; ULCERATIVE COLITIS; CHEMISTRY; CROSS-SECTIONAL STUDY; ENDOSCOPY; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; MIDDLE AGED; PATHOLOGY; SERUM; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADALIMUMAB; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CROSS-SECTIONAL STUDIES; ENDOSCOPY; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MIDDLE AGED; SERUM; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890219983     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.07.010     Document Type: Article

References (16)

1. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
2. Sandborn W.J., van Assche G., Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142. 257-265 e1-e3.
3. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
4. Takahashi H., Tsuji H., Ishida-Yamamoto A., et al. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. JDermatol 2013, 40:39-42.
5. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
6. West R.L., Zelinkova Z., Wolbink G.J., et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008, 28:1122-1126.
7. Hebuterne X., Lemann M., Bouhnik Y., et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013, 62:201-208.
8. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
9. Seow C.H., Newman A., Irwin S.P., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
10. Van Moerkeroke W., Ackaert C., Compernolle G. High infliximab trough levels are associated with mucosal healing in Crohn's disease. Gastroenterology 2010, 5:S60.
11. Frenz M.B., Dunckley P., Camporota L., et al. Comparison between prospective and retrospective evaluation of Crohn's disease activity index. Am J Gastroenterol 2005, 100:1117-1120.
12. Rutgeerts P., Van Assche G., Sandborn W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012, 142:1102-1111 e2.
13. Nanda K.S., Cheifetz A.S., Moss A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013, 108:40-47. quiz 48.
14. Mazor Y., Koplov K., Ben Huret D. Evaluating adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn's disease patients. JCrohn's Colitis 2013, 7(suppl 1):S217.
15. Chiu Y.L., Rubin D.T., Vermeire S., et al. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis 2013, 19:1112-1122.
16. Nanda K.S., Cheifetz A.S., Moss A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013, 108:40-47. quiz 48.